Voltar
Carta Acesso aberto Revisado por pares
BIBTEX RIS

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN

2022; Springer Nature; Volume: 12; Issue: 4 Linguagem: Estoniano

10.1038/s41408-022-00653-1

ISSN

2044-5385

Autores

Ajay K. Nooka, Jonathan L. Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne A. Efebera, Brandi Reeves, Tanya M. Wildes, Sarah A. Holstein, Larry D. Anderson, Ashraf Badros, Leyla Shune, Ajai Chari, Huiling Pei, Annelore Cortoos, Sharmila Patel, J. Blake Bartlett, Jessica Vermeulen, Thomas S. Lin, Paul G. Richardson, Peter M. Voorhees,

Tópico(s)

PI3K/AKT/mTOR signaling in cancer

Resumo

Daratumumab plus lenalidomide

Referência(s)